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Editorial 
Dear Reader 
There are various phases and methods in the 
life cycle of a medicinal product for recording 
potential risks. 
When applying for the authorisation of a new 
medicinal product, the prospective authorisa-
tion holder has to submit documentation on 
efficacy, quality and drug safety. The benefit-
risk profile is established by means of phar-
macological testing and, in particular, by 
clinical trials during the authorisation phase. 
However, since it is not possible to identify all 
risks, e.g. in certain patient groups and/or rare 
risks, during clinical trials, spontaneous re-
ports on unexpected adverse reactions (ADR) 
after the authorisation of a medicinal product 
provide valuable evidence of a particular 
safety signal. 
The recording of individual ADR reports and 
observational studies after widespread or 
long-term use play an important role. Known 
existing risks and the resulting risk minimisa-
tion measures should be checked at regular 
intervals, particularly in order to determine 
whether new findings might require a modi-
fication of the risk-benefit profile. This condi-
tion applies equally to new active substances, 
such as the antidotes for the substance class 
of direct oral anticoagulants (DOAC), and to 
familiar medicinal products that have been 
around for a long time. In this edition of 
Swissmedic Vigilance News we report on up-
dates to isotretinoin and psychiatric disorders, 
the risk of overdose arising from confusion 
between amphotericin B formulations and on 
the toxicity profile of morclofone. 
A periodic overview of the evaluation of any 
risks and signals is provided by the PSUR (Pe-
riodic Safety Update Report) for a medicinal 
product, which is prepared by the corre-
sponding authorisation holder. An article on 
PSUR takes a closer look. 
Current changes in drug safety are also shown 
by the 2017 annual statistics for pharmacovig-
ilance and vaccinovigilance. 
In vigilance in particular, it is extremely im-
portant to provide information to, and obtain 
feedback from, the affected patient groups 
and healthcare professionals. The “Guidelines 
for Quality Assurance in Transfusion Practice” 
were developed to protect patients from 
transfusion errors and resulting harm. 
Monitoring on site in hospitals, as in other in-
stitutions, is essential to ensure that thera-
peutic products remain safe. This fact is high-
lighted by the guest article on quetiapine in 
retirement homes in Ticino prepared by the 
Regional Pharmacovigilance Centre (RPVC) in 
Ticino. 
Another guest article, this time from the RPVC 
in Zurich, describes in detail the work of 
“RPVC collaboration”, illustrated by a case re-
port. The exchange of information and com-
munication between healthcare professionals 
and patients, the RPVC and the national Phar-
macovigilance Centre at Swissmedic and the 
authorisation holders are key factors in as-
sessing the potential risks associated with a 
medicinal product. 
The Editors 
Please send any suggestions or feedback on this issue of 
Swissmedic Vigilance News to: 
news.vigilance@swissmedic.ch. 
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Drug safety and signals
Medical monitoring of psychiatric 
disorders in patients taking oral 
isotretinoin for severe acne – Update 
Introduction 
During the clinical development of a drug, 
only the most common adverse reactions 
which are primarily attributable to the phar-
macological mechanism can be identified. 
Once a drug is launched on the market, the 
patients receiving the drug become more 
numerous and heterogeneous, potentially 
altering the safety profile of the drug.  
Therefore, side effects of medicines ob-
served in daily medical practice must be re-
ported, in accordance with the current Ther-
apeutic Products Act, so that safety data, 
which are still inevitably incomplete when 
the medicines are launched on the market, 
can be collated by Swissmedic. 
The following patient history was taken 
from an adverse drug event report for-
warded to Swissmedic by a regional pharma-
covigilance centre. The aim of this article is 
to use this specific example to illustrate the 
potential risk of the onset of psychiatric side 
effects during oral treatment with isotret-
inoin. 
Completed with due care and attention, this 
article is intended to alert healthcare profes-
sionals to the problem and provide them 
with useful information for patients suffer-
ing from severe acne and for whom oral 
treatment with isotretinoin is indicated. 
Case narrative 
The report concerns a 15-year-old male ado-
lescent with a severe form of acne that failed 
to respond to standard therapeutic cycles, 
including systemic antibiotics and topical 
treatment. Treatment with oral isotretinoin 
was started in April 2016. The patient was 
not taking any other medication. Three 
weeks after starting the treatment, in May 
2016, the patient attempted to commit sui-
cide with his mother's painkillers, specifically 
ibuprofen tablets, although the total in-
gested dose is not known. He was admitted 
to the emergency department the same day 
and remained clinically stable. The labora-
tory test results showed no abnormalities. 
He was transferred to a psychiatric hospital 
a few days later. Although it was difficult to 
obtain a history from the patient because he 
was very withdrawn, he did not describe any 
previous psychiatric problems. Nor did the 
history taken from his parents reveal any rel-
evant issues. The treatment with isotretinoin 
was discontinued in this young patient fol-
lowing his suicide attempt. The adolescent, 
who remained in hospital for several weeks, 
showed a slight improvement in mood, with 
the disappearance of suicidal thoughts, fol-
lowing the introduction, according to the 
history, of a quetiapine-based antidepres-
sant in the form of tablets. 
Discussion 
Acne is a disabling facial skin disorder, par-
ticularly in its severe form that can have sig-
nificant social and psychological conse-
quences and also interfere with the activities 
of daily living. 
The term "depression" covers a large and 
wide variety of possible meanings. The nu-
ances range from sadness to despair, via in-
ertia, lack of energy, with the possibility of 
black thoughts and even suicide. 
Isotretinoin, the treatment of choice for se-
vere cases of acne, is a systemic retinoid.  
Although abundant medical literature is 
available on the subject of psychiatric disor-
ders, the onset of depression and mood dis-
orders, the causality of oral isotretinoin is 
still a matter of debate, particularly since 
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acne itself can lead to depressive symptoms. 
Indeed, the rate of depressive symptoms is 
higher in patients suffering from acne than 
in non-sufferers. The incidence of suicidal 
thoughts and mental health problems is 
higher in adolescents with severe acne than 
those with little or no acne. Consequently, 
the age of the target population has to be 
taken into account as a confounding factor. 
It is acknowledged that the data available 
on the subject of psychiatric disorders and 
treatment with oral isotretinoin are associ-
ated with a significant number of limitations 
that make it difficult to establish a clear link 
of causality. Numerous spontaneous reports 
of adverse events involve confounding fac-
tors, such as the concomitant medication 
and/or a medical history of psychiatric disor-
ders. Moreover, depending on the indication 
concerned, the epidemiological studies do 
not allow confounding factors to be ruled 
out. Nevertheless, the data presented in the 
form of case series, spontaneous reports of 
adverse drug events and the individual expe-
rience of patients are considered to be es-
sential. 
For the patient whose history is described in 
this article, a compatible chronology sug-
gests that the causality of isotretinoin in this 
clinical picture may be rated as possible. 
Moreover, the product information for 
orally administered isotretinoin-based drugs 
mention the rare onset of depression, aggra-
vation of a pre-existing depression, mood al-
terations, anxiety, tendency to aggressive-
ness, and the very rare occurrence of suicide 
attempts and suicide. The corresponding in-
formation on these drugs can be found via 
the following link: 
www.swissmedicinfo.ch. 
Provided they are considered as judicious, 
Swissmedic broadly supports the application 
of the measures decided in Europe (1) in re-
lation to products containing isotretinoin 
and, more generally, retinoid-based pro-
ducts. 
Medical monitoring 
In view of the target population and a pos-
sible underlying risk of psychiatric disorders, 
it is essential for healthcare professionals to 
warn their patients about the potential risk 
of psychiatric reactions associated with 
treatment with oral isotretinoin. In this con-
text, particular attention should be paid to 
patients suffering from, or with a history of, 
depression. It is also essential to look out for 
signs and symptoms that are precursors of 
depression during the course of treatment 
and to monitor these patients. If a patient 
develops psychiatric problems, the treat-
ment with oral isotretinoin may need to be 
stopped and, if necessary, appropriate treat-
ment initiated.  
Authors of the relevant literature usually re-
port that the symptoms appear from a few 
days to a few weeks after the start of treat-
ment and disappear following its termina-
tion. It is possible, however, that stopping 
the treatment with oral isotretinoin may not 
be sufficient to reduce the depressive symp-
toms, and that psychiatric or psychological 
measures may need to be put in place. Cases 
involving the reappearance of the symptoms 
when the treatment with oral isotretinoin 
was resumed have also been reported. 
All sound reasons, therefore, to undertake 
close medical monitoring of patients treated 
with oral isotretinoin for the onset of de-
pressive and suicidal thoughts. Ideally, the 
patient's own physician, as well as the der-
matologist, should also be involved in this 
monitoring. Before treatment is started, the 
patients themselves should be warned of the 
risks associated with the treatment in gen-
eral, and the risks of psychiatric side effects 
in particular. 
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Pharmacovigilance data in Switzerland on 
oral isotretinoin and psychiatric disorders 
As at April 2018, Swissmedic had received a 
total of 658 reports since 1991, 143 of which 
concern psychiatric side effects. In these re-
ports, oral isotretinoin was the suspected 
drug. In most cases the reports were submit-
ted spontaneously. However, in 2008, fol-
lowing a media appeal by a patient organi-
sation, an increased number of solicited re-
ports of side effects were submitted to Swiss-
medic, as shown in figure 1. Disregarding 
that particular year, the reporting rate for 
psychiatric side effects is relatively stable, av-
eraging 10 reports a year. Reports involving 
psychiatric problems represent around 20% 
of all the reports submitted to Swissmedic 
for oral isotretinoin.  
It should be mentioned that the spontane-
ous reporting system does not allow the in-
cidence of psychiatric side effects to be eval-
uated on the basis of the accumulated data 
(figure 1), nor does it allow any clear and de-
finitive causal relationship to be established 
between the psychiatric symptoms and the 
administration of oral isotretinoin treat-
ment. 
Figure 1: Oral Isotretinoin – Swiss reports from 1991 until April 2018 
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Conclusion 
Severe acne is far from being a trivial illness 
since it can have significant social and psy-
chological consequences for the sufferers. 
When these patients are treated with orally 
administered isotretinoin, it is important for 
healthcare professionals to be particularly 
vigilant in watching for possible signs of de-
pression and/or similar symptoms so that 
they are detected at an early stage, followed 
by their close medical monitoring and, if 
necessary, the initiation of appropriate 
treatment. 
Reporting adverse drug reactions 
Swissmedic recommends the use of its spe-
cially designed online portal for reporting 
adverse drug reactions (ADR). The Electronic 
Vigilance System (ElViS) is used to report 
ADR. All the necessary details can be found 
at www.swissmedic.ch.
Literature 
(1) European Medicines Agency, 23/03/2018: Updated 
measures for pregnancy prevention during retinoid 
use; Warning on possible risk of neuropsychiatric 
disorders also to be included for oral retinoids: 
http://www.ema.europa.eu/ema/in-
dex.jsp?curl=pages/news_and_events/news/2018/0
3/news_de-
tail_002928.jsp&mid=WC0b01ac058004d5c1 
(2) M. Le Moigne et Al, Rétinoïdes systémiques et 
troubles psychiatriques : une revue systématique 
de la littérature, Annales de Dermatologie et de 
Vénéréologie, Volume 143, Issue 12, Décembre 
2016, pages S262-S263 
(3) Sundström A et Al, J. Association of suicide at-
tempts with acne and treatment with isotretinoin: 
retrospective Swedish cohort study. BMJ. 2010 Nov 
11 ; 341 :c5812 
(4) Bremner JD et Al, Retinoic acid and affective disor-
ders: the evidence for an association. J Clin Psychi-
atry. 2012 Jan; 73(1):37-50. 
  
  
 
Swissmedic Vigilance News | Edition 21 – November 2018 8 | 39 
 
Development, authorisation and safety 
of antidotes for the substance class of 
direct oral anticoagulants (DOAC) – 
Update 
Since DOAC are being used with increasing 
frequency in clinical practice (1), the availa-
bility of an effective antidote is of consider-
able medical importance. The indications for 
these antidotes are life-threatening bleeds, 
emergency surgical procedures and elective 
procedures where the aim is to minimise the 
time needed to reverse the anticoagulation 
(1). We would now like to provide an over-
view of the current situation. 
Praxbind® (active ingredient idarucizumab), 
the antidote for the factor IIa inhibitor Pra-
daxa® (active ingredient dabigatran), was 
authorised in Switzerland in July 2016. We 
reported previously on the authorisation 
studies in our Vigilance News, edition 16 
(May 2016). Since these antidotes were au-
thorised, Swissmedic has received a total of 
four reports (as at 12 June 2018) of adverse 
drug reactions that were classified as serious. 
These involved the cardiovascular system, in-
cluding one thromboembolic event, and the 
nervous system. For all four reports the 
causal link with the administration of Prax-
bind® was rated as possible. At this point, it 
should be stated that, in order to be able to 
draw conclusions about the safety and toler-
ability of a drug, the underlying prescribing 
figures, which we do not have, need to be 
taken into account. 
Until recently, no specific antidote to factor 
Xa inhibitor has been available anywhere in 
the world. In May 2018, this changed follow-
ing the approval of andexanet alfa by the 
FDA (2). This antidote is capable of reversing 
the effect of direct (apixaban, edoxaban and 
rivaroxaban) and indirect (fondaparinux and 
low molecular weight heparins) factor Xa in-
hibitors (3). In a 2-arm phase III study, AN-
NEXA-A for apixaban and ANNEXA-R for 
rivaroxaban, the efficacy and safety of an-
dexanet alfa were tested in 145 healthy vol-
unteers aged between 50 and 75 in a pla-
cebo-controlled trial (3). In the test subjects 
treated with rivaroxaban, there was a me-
dian reduction of 97 % in factor Xa activity, 
while a median reduction of 92 % was ob-
served in those treated with apixaban (4). No 
thrombotic events occurred in any of the 
study participants. Antibodies to factor Xa 
were not detected in any of the trial sub-
jects. Nor were any neutralising antibodies 
to andexanet observed. Non-neutralising 
antibodies to andexanet were detected in 1 
of 44 trial participants receiving placebo and 
in 17 of 101 study subjects who were pre-
scribed andexanet. The fact that these anti-
bodies disappeared again after 15–30 days 
suggests that andexanet is not associated 
with significant immunogenicity. D-dimers 
and prothrombin fragments were temporar-
ily detected in increased amounts, but re-
turned to normal levels after 24–72 hours 
(3). 
Ciraparantag is a third antidote still under 
clinical trial. Structurally, it is a small, water-
soluble, synthetic molecule. Compared to 
andexanet alfa, ciraparantag is supposed to 
be capable of additionally reversing the 
effect of factor IIa inhibitors (Pradaxa®), and 
thus serves as an antidote for all DOAC and 
for both unfractionated and low molecular 
weight heparins (1, 5). A phase I study inves-
tigated the efficacy and safety of ciraparan-
tag (100–300 mg) after an initial dose of 
edoxaban (60 mg). The study enrolled 83 
healthy volunteers between 18 and 65 years 
old, 67 of whom received ciraparantag and 
16 placebo. A single dose of ciraparantag 
was able, after 10 minutes, to reverse the ef-
fect of edoxaban for 24 hours (5). No serious 
adverse drug reactions were observed, and 
no trial subject terminated the study prema-
turely due to such reactions. No significant 
blood count or ECG changes were regis-
tered. Procoagulant activity, measured by 
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specific changes in the D-dimers and pro-
thrombin fragments 1 and 2, remained ab-
sent. Facial flushing was observed in a few 
subjects immediately after the intravenous 
administration of ciraparantag (5). A phase 
II study that investigated the efficacy and 
safety of ciraparantag after the administra-
tion of rivaroxaban is scheduled to end in 
July 2018 (6). 
There is hope that many patients can now 
benefit from successful treatment with these 
agents, which have recently become availa-
ble for routine clinical use in the treatment 
of life threatening complications caused by 
haemorrhage. For a detailed assessment of 
the safety profile of the antidotes men-
tioned beforehand, final results from ongo-
ing clinical trials with ciraparantag must be-
come available. Moreover, postmarketing 
data for all new antidotes over a prolonged 
period of time is crucial to elucidate their 
safety profile. 
Literature 
(1) Hu TY, Vaidya VR, Asirvatham SJ. Reversing antico-
agulant effects of novel oral anticoagulants: role of 
ciraparantag, andexanet alfa and idarucizumab. 
Vascular Health and Risk Management. 2016; 
12:35-44. 
(2) http://www.mdmag.com/medical-news/fda-gives-
nod-to-andexanet-alfa-reversal-agent-for-rivarox-
aban-apixaban  
(3) Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, 
Paje DG. Reversing factor Xa inhibitors - clinical 
utility of andexanet alfa. Journal of Blood Medi-
cine 2017; 8:141-149. 
(4) Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley 
PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, 
Leeds JM, Mar FJ, Gold A, Crowther MA. Andexanet 
alfa for the reversal of factor Xa inhibitor activity. 
New England Journal of Medicine 2015; 373(25): 
2413-2424. 
(5) Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso 
MA, Brown K, Dishy V, Lanz HJ, Mercuri MF, Noveck 
RJ, Costin JC. Single-dose ciraparantag safely and 
completely reverses anticoagulant effects of edox-
aban. Thrombosis and Haemostasis 2017; 117(2): 
238-245 
(6) https://clinicaltri-
als.gov/ct2/show/NCT03172910?term=per977&rank
=6  
  
 
Swissmedic Vigilance News | Edition 21 – November 2018 10 | 39 
 
Favourable acute toxicity profile of 
morclofone in children 
Morclofone has been used since the 1980s as 
a centrally acting antitussive, mainly as a 
syrup in children with a dry non-productive 
cough. The standard single dose is 50 mg in 
children up to 3 years old and 150 mg in 
older children. 
A study group at Tox Info Suisse retrospec-
tively analysed 29 cases of acute intoxication 
with morclofone in children that were re-
ported to Tox Info Suisse between January 
1997 and June 2016. These reports involved 
10 girls and 19 boys with an average age of 
3 years (1.6–6 years). 
Eight children were asymptomatic and 21 
only had mild symptoms. The administered 
dose was known in 21 cases and ranged from 
31 to 171 mg/kg body weight (mean: 
64  mg/kg body weight), which corresponds 
to between 4 and 36 times the single thera-
peutic dose. The observed symptoms of vom-
iting (n=15), nausea (n=4), abdominal pain 
(n=4), drowsiness (n=6), ataxia (n=1) and 
tachycardia (n=1) were of short duration and 
regressed spontaneously. In 9 patients, gas-
trointestinal decontamination was per-
formed with a single dose of activated char-
coal, producing mild symptoms in 7 patients. 
Conclusion: Morclofone has a favourable 
acute toxicity profile, and significant over-
doses of up to 171 mg/kg body weight re-
sulted only in mild symptoms. Therefore, the 
monitoring of patients at home, without 
gastrointestinal decontamination, seems 
reasonable following the administration of 
doses below 171 mg/kg body weight. 
Literature 
Hofer KE, Kupferschmidt H, Rauber-Lüthy C. 
National Poisons Centre, Tox Info Suisse, Associated In-
stitute of the University of Zurich. Favorable acute tox-
icity profile of morclofone in children. 
Clinical Toxicology 55.5 (2017): 460 of the 37th Inter-
national Congress of the European Association of Poi-
sons Centres and Clinical Toxicologists 
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An interesting case: Unexpected cause 
of shock in a patient with tachycardio-
myopathy 
A study group at Basel University Hospital 
has reported on a 76-year-old male patient 
who had been referred to the emergency 
department by his GP (general practitioner) 
due to exercise-induced dyspnoea (NYHA 
grade II) lasting for 10 days. He took no med-
ication and had not received any medical 
treatment for the past 25 years. 
His GP noted the presence of tachycardia 
(140 bpm) and hypertension (146/107 
mmHg). The jugular veins were slightly dis-
tended, and blood gas analysis and respira-
tory rate were normal. 
Since an ECG showed atrial fibrillation, the 
patient was given 1 mg metoprolol intrave-
nously every 5 minutes to control his heart 
rate. After the administration of 3 mg of 
metoprolol, the patient developed severe 
orthopnoea. Blood pressure, heart and res-
piratory rates (up to 50/min) rose substan-
tially, and the jugular veins were markedly 
distended. The ultrasound showed signs of 
right heart failure, while ruling out a pneu-
mothorax and a pericardial tamponade. His 
blood pressure subsequently dropped to the 
point where it was no longer measurable, 
and his extremities were cold. The treating 
physicians assumed that the shock had been 
caused by pulmonary embolism and admin-
istered 10 mg rt-PA (recombinant tissue-type 
plasminogen activator), which produced an 
improvement in the patient's clinical condi-
tion. A pulmonary embolism was subse-
quently ruled out by a CT scan. Echocardiog-
raphy showed tachycardiomyopathy of un-
known origin, with a left ventricular ejection 
fraction of only 17 %. 
 
Conclusion: Even low doses of a beta blocker 
can provoke shock in patients with tachycar-
diomyopathy and a very low left ventricular 
ejection fraction. The authors assumed that 
the clinical improvement was attributable to 
the short half-life of the intravenous 
metoprolol or a hypothetical interaction 
with rt-PA that diminished the effect of 
metoprolol. 
This literature report was submitted to us by 
a pharmaceutical company that distributes 
metoprolol in Switzerland. Like traditional 
spontaneous reports, Swissmedic continu-
ously assesses literature reports and reviews 
them in particular for their signal impact. 
Literature 
Spiegel R, Haefelfinger R, Sutter R, Bingisser R. An un-
expected cause of shock in a patient with tachycardio-
myopathy. Critical Care Medicine. 2018;46(1):143. DOI: 
10.1097/01.ccm.0000528341.94497.d1. 
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Confusion between amphotericin B 
formulations: Risk of overdose 
Amphotericin B 
Amphotericin B is a polyene antibiotic iso-
lated from Streptomyces nodosus. Its mech-
anism of action is based on the reaction with 
the sterols in the cell membranes of sensitive 
fungi, thereby disrupting the membrane 
function and partially damaging the mem-
brane structure. Amphotericin B is indicated 
for the treatment of patients with invasive 
fungal infections. The most frequent side ef-
fects include hypersensitivity reactions, in-
flammation of the tongue, nausea, vomit-
ing, diarrhoea and skin rashes; the most 
problematic feature is the pronounced ne-
phrotoxic potential of the substance (1, 2). 
Since amphotericin B is hardly absorbed at 
all from the gastrointestinal tract, ampho-
tericin B must be administered parenterally 
for the treatment of systemic fungal infec-
tions. Amphotericin B is therefore marketed 
in non-liposomal and liposomal forms.  
Despite the fact that both contain the same 
active substance and identical antimycotic 
spectrum of action, the dosages of ampho-
tericin B are product-specific and must not 
be applied to other medicines containing 
amphotericin B: For conventional (non-lipo-
somal) amphotericin B, the maximum daily 
dose of 1.5 mg/kg body weight should not 
be exceeded (1); for liposomal amphotericin 
B, on the other hand, the maximum dosage 
is 3 to 6 mg/kg/day (2). 
Reports of mix-ups between medicines con-
taining amphotericin B and liposomal am-
photericin B, with serious adverse events, in-
cluding cases with a fatal outcome, are de-
scribed in the literature (3, 4). 
DHPC in France 
On 22 May 2017, Bristol-Myers Squibb (BMS), 
Gilead Sciences and Acino Pharma, in consul-
tation with the French authority ANSM 
(Agence nationale de sécurité du médica-
ment et des produits de santé), distributed a 
Direct Healthcare Professional Communica-
tion (DHPC) in France concerning the risk of 
overdosage of amphotericin B (5). Mix-ups 
had occurred between non-liposomal and 
liposomal parenteral forms. Since the prepa-
ration of the infusion solutions, the dosages 
and the rate and duration of administration 
differ between the formulations, there is a 
risk of drug errors. These errors mainly in-
volve the administration of Fungizone® and 
the possibility of amphotericin B overdose 
with potentially serious cardiac and renal 
damage as a result of a mix-up. 
Situation in Switzerland 
Current risk-minimising measures 
Following the publication of the DHPC in 
France, marketing authorisation holders and 
the competent drug regulatory authorities 
in all countries where differing amphotericin 
B formulations are marketed are investigat-
ing whether changes need to be made to the 
relevant summaries of product characteris-
tics (SPC) and whether the risks need to be 
communicated to corresponding healthcare 
professionals via a DHPC, as in France. 
The following parenteral formulations of 
amphotericin B are currently available on 
the market in Switzerland: Bristol-Myers 
Squibb SA distributes Fungizone® (non-lipo-
somal amphotericin B), the conventional 
form based on deoxycholate amphotericin B. 
Gilead Sciences Switzerland Sàrl distributes 
AmBisome®, which contains liposome-bound 
amphotericin B.  
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In order to highlight the risk of confusion, 
the Swiss Information for healthcare profes-
sionals for Fungizone® already contains the 
following warnings: 
"Multiple parenteral forms of the active sub-
stance amphotericin B exist. Please check the 
preparation name and dosage before use. 
Caution during Fungizone dosing: Under no 
circumstances should a total daily dose of 1.5 
mg/kg body weight be exceeded. An over-
dose can result in potentially fatal cardiac or 
respiratory arrest." 
In view of the higher permitted dosage of 
AmBisome®, the problem of overdose arises 
when Fungizone® is administered at the Am-
Bisome® dosage. By contrast, using AmBi-
some® instead of Fungizone® can lead to un-
derdosage. The product information for Am-
Bisome® explicitly refers to this in the dosage 
section: 
"Since the dosage of AmBisome is product-
specific it may NOT be applied to other med-
icines containing amphotericin B." 
Case reports 
The product information texts and packag-
ing elements of Fungizone® and AmBisome® 
already include sufficient references to the 
risk of confusion and the associated risk of 
overdose. Nevertheless, there are two 
known cases in Switzerland where the dos-
age recommendations for liposomal ampho-
tericin B were applied to the administration 
of non-liposomal amphotericin B. 
In 2015, a 39-year-old woman received an 
overdose with non-liposomal amphotericin 
B, resulting in multiple life-threatening 
events (ventricular tachycardia, cardiac ar-
rest, hyperkalaemia, acute kidney injury, 
liver cell damage, haemolytic anaemia and 
thrombocytopenia). By the time of the re-
port, the patient had recovered from the 
cardiac arrest and hyperkalaemia, but not 
from the acute liver damage, haemolytic 
anaemia or thrombocytopenia. 
In a case from Switzerland published in 2016, 
an immunosuppressed 9-year-old boy recov-
ering from a bone marrow transplant suf-
fered diarrhoea, vomiting, acute renal fail-
ure, fever and shivering as a result of an am-
photericin B overdose. The patient had been 
given Fungizone® instead of the prescribed 
intravenous AmBisome®. Consequently, the 
patient had received ten times the recom-
mended dose. After rehospitalisation and 
several weeks of treatment, the child recov-
ered completely (6). 
Conclusion 
The purpose of a Direct Healthcare Profes-
sional Communication (DHPC), formerly 
termed a Dear Doctor Letter (DDL), is to in-
form health professionals about important, 
newly identified drug risks – particularly if 
these are unexpected – and corresponding 
risk minimisation measures, with a view to 
prompting a relevant change in approach. In 
this case, the product information texts and 
packaging elements for the drugs concerned 
already contained sufficient references to 
the risk of confusion and thus the associated 
risk of overdose. The risk of confusion is 
known in professional circles and published 
in the literature. The information in these 
texts should already have been taken into 
account by the treating professionals. In this 
specific case, Swissmedic is therefore not 
sending out a DHPC, but would like to re-
mind professionals of the risk of mix-ups be-
tween non-liposomal and liposomal paren-
teral forms of amphotericin B. Since the dos-
age of amphotericin B preparations is prod-
uct-specific it may not be applied to other 
medicines containing amphotericin B. In 
view of the parallel use of different ampho-
tericin B solutions in hospitals, measures 
should be taken to make it impossible, or at 
least more difficult, to confuse these prepa-
rations. 
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Guest article 
Pharmacovigilance, drug safety and 
knowledge transfer:  
The Swiss RPVC Approach 
Stefan Weiler (1), (2) 
as part of the Swiss RPVC collaboration, consisting of 
the Regional Pharmacovigilance Centres in Geneva, 
Lausanne, Bern, Basel, Ticino, Zurich 
(1) Regional Pharmacovigilance Centre Zurich, Depart-
ment of Clinical Pharmacology & Toxicology, Uni-
versity Hospital Zurich and University of Zurich 
(2) Tox Info Suisse, Associate Institute of the University 
of Zurich 
“The doctor prescribes medicines about 
which he knows little to patients about 
whom he knows even less.” 
Ahmed Wilfried Waba, WHO, 1984 
Diagnosis: 
"Adverse Drug Reaction" 
Adverse drug reactions (ADR) are medica-
tion-induced conditions whose symptoms 
mimic those that can themselves be caused 
by illnesses. Headache, dizziness, diarrhoea 
or vomiting are temporary and reversible 
symptoms that can occur as part of a viral in-
fection for example. By contrast, other con-
ditions such as carcinogenesis are protracted 
processes that can be promoted by various 
factors. It is often difficult to separate out 
the various aetiologies and weigh up the 
risks factors on both sides. Physicians are 
trained to diagnose, define and “success-
fully” treat diseases. Medicines are devel-
oped and manufactured to cure patients, or 
at least improve their condition. But the 
other side of the pharmacological coin can 
soon be forgotten. 
 
”If it is claimed that a substance has no side 
effects, then there is a strong suspicion that 
it does not have any principal effect.” 
Gustav Kuschinsky, 1904-1992 
Diagnostic investigations of adverse reac-
tions are usually based on the exclusion of 
other causes. Laboratory markers that clearly 
diagnose an adverse reaction are not pre-
sent in many cases. Like other tests, such di-
agnostic methods – e.g. HIT antibody assay – 
possess a sensitivity and specificity that al-
lows for the possibility of false-positive and 
false-negative results. So it’s not so easy to 
pinpoint the culprit (the suspected drug)! 
And this is what pharmacovigilance is all 
about: Criteria such as latency period, course 
of the reaction, frequency, severity, repro-
ducibility, mechanism or nature of the ad-
verse reaction strengthen the diagnosis of a 
drug-induced illness. 
Descending from the ivory tower: 
Knowledge transfer in pharmacovigilance 
Acting on behalf of Swissmedic, the Re-
gional Pharmacovigilance Centres (RPVC) 
are responsible in Switzerland for receiving 
and processing ADR reports from healthcare 
professionals, patients and consumers. The 
RPVC are usually linked with the Clinical 
Pharmacology and Toxicology departments 
of the university hospitals. Clinical pharma-
cology is a medically and scientifically estab-
lished discipline in Switzerland that ad-
dresses the rational and safe use of pharma-
ceutical products in humans. Drug safety and 
pharmacovigilance are core areas of clinical 
pharmacology and toxicology, where you 
will find experts who help record, prioritise 
and process ADR. They support the detection 
of potential signals and the flow of infor-
mation to the primary reporter, the authori-
ties and, under certain circumstances, to the 
public as well. On the other hand, those who 
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frequently report ADR are patients who are, 
or were, themselves affected or profession-
als who use or dispense therapeutic products 
on a commercial basis. The latter are also 
obliged by the Swiss Federal Act on Medici-
nal Products and Medical Devices to report 
serious or previously unknown ADR. But nu-
merous wide-ranging reasons are presented 
for nevertheless not reporting ADR. These 
include: 
 erroneous assumptions that only safe 
medicines are on the market and that an 
ADR is therefore not possible. 
 fear of becoming entangled in a legal 
dispute or of losing the patient's trust. 
 subjective feelings of guilt that a medi-
cine may have harmed more than 
helped. 
 personal ambition to collect and publish 
case reports (publish or perish). 
 unwillingness to report a drug-induced 
reaction solely on the basis of a suspicion 
without a definite connection, or simply 
the lack of time and interest: “The bu-
reaucracy and completion of forms won’t 
help improve my patient’s situation.” Pri-
mary reporters are also not reimbursed 
for their time and intellectual input. 
Many of these possible reasons involve an 
active reluctance to report an ADR. How-
ever, an unintentional reticence should not 
be overlooked: the lack of knowledge con-
cerning pharmacological principles, patho-
physiological explanations of dose-depend-
ent effects and side effects, the fundamental 
inclusion of an ADR in the differential diag-
nosis during the investigation of symptoms. 
In 2017 in Switzerland, 36,900 physicians 
(32,586 full-time equivalents) were em-
ployed in a wide variety of fields (SMF 2018; 
99 (13-14): 408-413). 51% of these work in 
the outpatient environment and 47% in the 
inpatient sector. Many use medicines as 
treatments – but how many of them possess 
a sound knowledge of pharmacological prin-
ciples that goes beyond the respective indi-
cation, dosage and certain warnings? 
So in 2016 all RPVC in Switzerland and Tox 
Info Suisse – the National Poisons Centre re-
sponsible for all questions and information 
related to overdoses – merged in a collabo-
rative venture with the aim to focus people’s 
attention on drug safety (see SMF 
2016;16(37):757–763). Together with the 
Swissmedic National Pharmacovigilance 
Centre, the decision was taken to provide 
regular educational articles consisting of 
clinically relevant pharmacovigilance cases 
with a subsequent pharmacological or toxi-
cological explanation. The medium chosen 
for this purpose was the official training or-
gan of the Swiss Medical Association (FMH), 
i.e. the most widely read medical education 
journal in Switzerland. The "Swiss Medical 
Forum” appears weekly in German and 
French, with a total circulation of 38,110 
copies in Switzerland. This ensures that is-
sues of relevance to drug safety are given 
the widest possible dissemination. The exist-
ing pharmacological and toxicological ex-
pertise is provided to refresh drug-related 
knowledge, place it in a clinical context and 
present it concisely and succinctly using case-
based analyses. The higher-level aim is to im-
prove drug safety in Switzerland, maintain 
standards of prescribing and, last but not 
least, increase national patient safety. 
Decant and carafe: Choosing the right 
vessel 
Every day physicians take countless histories. 
They ask questions about current symptoms, 
previous illnesses, familial predisposition, 
work, risk factors and many other matters. 
So physicians listen to countless histories 
from their patients. But they also like to read 
patient (hi)stories, since they are much more 
familiar with them from their daily clinical 
work than with statistics or methodological 
indicators. The RPVC collaboration therefore 
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agreed on the format of a brief case descrip-
tion of the ADR: How old? How serious? 
What medicine was used, why and at what 
dosage? What was the latency period prior 
to what symptoms? What was investigated 
in the differential diagnosis? What hap-
pened then? Were countermeasures initi-
ated? Were there any predisposing factors, 
such as allergies, renal impairment or liver 
disease? 
Subsequent to the case report, a clinically-
based pharmacological or toxicological as-
sessment of the case is provided, in which 
classical sources are presented as helpful 
guidance. The assessment is based on the 
Swiss product information of the drug 
which, in contrast with many other coun-
tries, is freely available on the Internet, at 
www.swissmedicinfo.ch. Depending on the 
clinical case and the ADR, drug-drug interac-
tions, drug-herb interactions, drug-food in-
teractions and drug-disease interactions are 
also discussed. A failure to recognise the 
ADR can result in prescribing cascades. Risk 
factors for the respective ADR – e.g. ad-
vanced age, poor compliance, substances 
with a narrow therapeutic range, multimor-
bidity, hepatic/renal impairment and 
polypharmacy – are included in the analysis. 
These factors may be associated with an in-
creased risk of altered pharmacodynamics in 
terms of an increased response, pharmacoki-
netic and pharmacodynamic interactions or 
the patient’s limited compensation mecha-
nisms. Other medical causes that may not yet 
have been excluded are also presented, to-
gether with case-related evidence and the 
pathophysiological plausibility for the re-
spective reaction. The question as to 
whether the reaction could have been 
avoided is often posed. Were potential 
sources of error present, such as system-re-
lated risk factors with transcription errors, 
mix-ups, incorrect administration or multiple 
prescribing? Are there medical/pharmaco-
logical alternatives to the drug that may 
have caused the reaction? 
An example of such a case description with 
subsequent assessment is shown below. 
The clinical case: Acute hepatitis during the 
administration of amoxicillin/clavulanic 
acid 
The 58-year-old male patient presented at 
the hospital with severely itching jaundice 
and general malaise. Following a yellow fe-
ver vaccination (3 months previously), he 
had travelled to Tanzania, where he had de-
veloped swallowing difficulties two weeks 
ago. He also suffered from a blocked nose 
and earache. As treatment he took Triofan® 
(carbocisteine, xylometazoline) nasal spray, 
Mebucaine® f (tyrothricin, cetylpyridinium, 
oxybuprocaine), Voltaren® Dolo liquid Caps 
12.5mg (diclofenac) and two sachets of Neo-
Citran® (phenylephrine, pheniramine, ascor-
bic acid, paracetamol). Since the symptoms 
continued to deteriorate, he returned home 
prematurely after a few days and visited his 
physician, who diagnosed an upper respira-
tory tract infection and bilateral otitis me-
dia. The C-reactive protein level (CRP) was 
48 mg/L (normal: <5 mg/L). The streptococcal 
rapid test was negative, and the EBV serol-
ogy did not show any evidence of an acute 
infection. Antibiotic treatment was initiated 
with Co-Amoxi Mepha® (amoxicillin/clavu-
lanic acid) 1g twice daily. He also took Spiri-
cort® (prednisolone) 5mg, Neo Spirig® HC na-
sal spray (xylometazoline) and Olfen® 50mg 
(diclofenac) to reduce swelling. While the 
patient’s symptoms had improved on the an-
tibiotic treatment that he had been taking 
up until a week previously, his urine turned 
a dark beer-colour for the first time after a 
few days and he was sleeping poorly. Two 
days before presenting at the hospital, the 
patient noticed itching for the first time. On 
the following morning he became increas-
ingly listless and had a diminished appetite. 
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During the previous week he had lost 2 kg in 
weight despite following a normal diet. 
On admission to hospital, the patient then 
passed a whitish stool for the first time. La-
boratory tests showed elevated liver param-
eters: 
 
 
 Reference Admission +4 days +8 days +15 days +26 days 
ALT <50 U/l 395 253 330 81 22 
AST <50 U/l 120 120 137 25 22 
GGT <61 U/l 494 360 246 126 65 
ALP 40-129 U/l 403 488 329 170 98 
Bilirubin 
(total) 
<21µmol/l 72 37.5 19.4 14.1 13.8 
Table 1: Course of liver function parameters in relation to the day of admission. ALT 
alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transferase, 
ALP alkaline phosphatase 
 
 
The hepatitis serologies and the HIV, CMV, 
HSV, EBV, syphilis screening tests and the 
malaria rapid test were negative. The INR 
was 1.2, albumin was normal, the eGFR was 
79ml/min/1.73 m2. 
On the abdominal ultrasound scan the liver 
appeared normal apart from a known hae-
mangioma in the left lobe. Acute hepatitis 
was diagnosed on the basis of the laboratory 
results and the patient’s symptoms (table 1). 
Already by the 5th day after admission, i.e. 
11 days after the antibiotic had been discon-
tinued, the pruritus had started to regress 
and the patient’s stools were less white. 
However, the patient's urine remained a 
dark colour. The liver enzymes subsequently 
also regressed: 32 days after discontinuation 
of the antibiotic, the transaminase levels, bil-
irubin and ALP had all returned to the refer-
ence range. 
The patient had suffered an episode of acute 
cholestatic hepatitis three years previously. 
At that time a cefuroxime-induced cause had 
been suspected in the aetiology. The pa-
tient’s mother had suffered from jaundice in 
the past. 
Clinical pharmacological / toxicological 
assessment 
Drug-induced liver injuries (DILI) are pre-
dominantly idiosyncratic and do not show 
dose-dependency for the substances used – 
comparable to a hypersensitivity reaction, 
e.g. with interstitial nephritis. Dose-depend-
ent exceptions for DILI apply in the case of a 
hepatotoxic effect due to the paracetamol 
metabolite NAPQI. DILI is currently an exclu-
sion diagnosis, since no specific biomarkers 
are yet available (Weiler et al. 2015). Three 
categories are differentiated: hepatocellu-
lar, cholestatic or mixed liver injury. The in-
jury pattern can be determined using the ra-
tio R, where R = ALT/ULN_ALT/ALP/ULN_ALP, 
according to the enzyme configuration for 
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alanine aminotransferase and alkaline phos-
phatase. An R ≥ 5 is indicative of a hepato-
cellular injury, which often occurs in parace-
tamol poisoning, with anti-infective agents 
such as ciprofloxacin, isoniazid, antihyper-
tensive substances such as lisinopril, or 
statins. Amoxicillin/clavulanic acid, erythro-
mycin, steroids, oral contraceptives, 
clopidogrel, irbesartan and tricyclic antide-
pressants often lead to a cholestatic pattern 
(R ≤ 2). Mixed forms of hepatic injury (R >2 
and <5) are found, for example, during 
treatment with nitrofurantoin, anabolic 
steroids, verapamil, enalapril, carbamaze-
pine and phenytoin, but also erythromycin 
or amoxicillin/clavulanic acid. In this case, 
there was a mixed pattern on admission (on 
admission R=2.5) with an elevated bilirubin 
level. In the differential diagnosis, serology 
tests and ultrasound showed no evidence of 
any other possible causes in this case. 
The following relevant adverse drug reac-
tions are described in the Swiss Information 
for healthcare professionals for amoxicil-
lin/clavulanic acid: 
“Co-Amoxi® Mepha:  
Uncommon: Moderate rises in the AST 
and/or ALT levels, temporary rise in lactate 
dehydrogenase and alkaline phosphatase 
levels. 
Rare: Hepatitis and cholestatic jaundice.” 
Treatment with diclofenac and paracetamol 
usually results in purely hepatocellular cell 
damage, whereas beta-lactam antibiotics 
such as amoxicillin/clavulanic acid show a 
predominantly mixed to cholestatic pattern 
(Hussaini et al. 2014). 
The incidence of this adverse reaction to 
amoxicillin/clavulanic acid is approx. five 
times higher than for amoxicillin alone, and 
is estimated to occur in approx. 1 in 2,500 
prescriptions. According to “NIDDK 
Livertox”, the combination of amoxicil-
lin/clavulanic acid is currently the most fre-
quent cause of DILI in most large case series 
in Europe and the USA. The symptomatic on-
set typically involves the appearance of fa-
tigue, mild fever, nausea and abdominal 
pain, followed by pruritus and jaundice. The 
latency period ranges from a few days to 
eight weeks after the start of treatment, i.e. 
usually after the cessation of the antibiotic 
treatment. While the mechanism for the 
liver damage is not known, an immunoaller-
gic origin is suspected. Fever, joint pains, skin 
rash and eosinophilia are described as ac-
companying signs and symptoms. The risk 
appears to be slightly increased with a pro-
longed treatment period, age ≥ 65 years and 
in men. An HLA association is suspected 
(DRB1*15:01-DRB5*01:01-DQB1*06:02). The 
symptoms and findings (particularly ele-
vated ALP and GGT levels) are usually re-
versible – as in the case described above (ap-
prox. 1 month after discontinuation of the 
antibiotic). 
Although a temporal relationship with the 
Triofan®, Mebucain® f, Voltaren® Dolo, 
NeoCitran®, Spiricort®, Neo Spirig® HC and 
Olfen® cannot formally be ruled out, the pa-
tient had already suffered an episode of cho-
lestatic hepatitis a good two years previ-
ously, when cefuroxime had been suspected 
as the cause. As a cephalosporin, and like the 
broad-spectrum penicillin amoxicillin/clavu-
lanic acid, cefuroxime is also a beta-lactam 
antibiotic with a similar structure (Weiler & 
Corti 2014). Köklü and colleagues described 
a 23-year-old male patient who experienced 
cholestatic hepatitis after taking cefurox-
ime. The same patient had previously suf-
fered an episode of cholestatic hepatitis 
while taking ampicillin. A cross-reactivity 
with an idiosyncratic reaction due to toxic 
metabolites was suspected in this case. 
Given the temporal relationship, the typical 
picture of liver injury, the very good docu-
mentation in the literature and the previous 
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episode of hepatitis while taking the beta-
lactam cefuroxime, the causality between 
the acute hepatitis and amoxicillin/clavu-
lanic acid was formally rated as probable ac-
cording to the CIOMS/WHO criteria. 
The following measures were recom-
mended: the issuing of an allergy card for 
beta-lactams, the alternative use of other 
antibiotic groups with no structural similar-
ity, such as macrolides or fluoroquinolones, 
or the administration of beta-lactams only in 
life-threatening situations. 
The Swiss RPVC Approach: Lessons for the 
future 
The Swiss spontaneous reporting system for 
postmarketing safety monitoring enables 
medical professionals to report ADR to phar-
macovigilance centres. Such systems allow 
physicians and pharmacists to become di-
rectly involved in the safety monitoring sys-
tem and can help them in their duty to re-
port reactions as required by the Swiss Fed-
eral Act on Medicinal Products and Medical 
Devices. Detailed information on relevant 
symptoms, diagnostic results, history details, 
concomitant medication and the subsequent 
clinical outcome of the ADR can be reported 
using these systems. This detailed infor-
mation directly from the healthcare profes-
sional is particularly important for ADR that 
are serious or rare, and is also an essential 
component of the postmarketing pharma-
covigilance system. The remit is very broad 
and encompasses all medicines that are used 
by the general public (table 2). 
 
 
ADR Medicine(s) Reference URL 
Pancytopenia Methotrexate Schweiz Med Forum 
2017;17(2829):594-596 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2017.03013/  
Type II thrombocytopenia Heparin Schweiz Med Forum 
2017;17(33):676-677 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2017.03036/  
Perforated duodenal ulcer Naproxen Schweiz Med Forum 
2017;17(36):756-759 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2017.03053/  
Overdose after administration 
error 
Buprenorphine Schweiz Med Forum 
2017;17(38):806-807 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2017.03055/  
Bilateral achillodynia Ciprofloxacin Schweiz Med Forum 
2018;18(06):123-124 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2018.03201/  
Hemiballism Cinnarizine Schweiz Med Forum 
2018;18(07):145-146 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2018.03198/  
Restlessness, malaise and trem-
ors in opioid withdrawal syn-
drome 
Nalmefene Schweiz Med Forum 
2018;18(1314):295-296 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2018.03206/  
Palpitations Xylometazoline Schweiz Med Forum 
2018;18(1920):415-416 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2018.03255/  
Extrapyramidal symptoms Metoclopramide Schweiz Med Forum 
2018;18(10):220-221 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2018.03204/  
Weakness, bradycardia, visual 
disturbance, hyperkalemia 
Digoxin Schweiz Med Forum 
2018;18(22):460-462 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2018.03200/  
Haemorrhage and Vitamin-K 
deficiency 
Orlistat Swiss Med Forum. 
2018;18(23):479-481 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2018.03293/  
Acute liver failure Repeated 
paracetamol 
Schweiz Med Forum 
2018;18(21):437-439 
https://medicalforum.ch/de/ar-
ticle/doi/smf.2018.03257/  
Table 2: Examples of adverse drug reactions with corresponding medicines 
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Despite the advances made in the field of bi-
omarkers or pharmacogenetics and phar-
macogenomics, a comprehensive history of 
previous intolerances will definitely con-
tinue to be essential in future. So the right 
questions will still need to be asked even 
when specific tests and biomarkers for de-
tecting adverse reactions become available. 
The transfer of knowledge from the expert 
to the prescribing physician with a basic 
pharmacological understanding of side ef-
fects intends to strengthen the system, while 
the knowledge from routine clinical practice 
should help improve the detection of safety 
signals. The future will show how the devel-
opment of a wide variety of communication 
resources can contribute towards the optimi-
sation of medicines and patient safety, not 
to mention the benefit-risk assessment both 
in the individual and in large parts of the 
population. 
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Introduction 
In recent years, the use of second-generation 
neuroleptic agents, also known as atypical 
neuroleptics, has been steadily on the rise in 
the western world, including in connection 
with off-label prescriptions – i.e. outside the 
officially authorised indications (treatment 
of schizophrenia and manic-depressive epi-
sodes in bipolar disorder) and particularly 
for the treatment of agitation, dementia, in-
somnia, personality disorders, generalised 
anxiety disorders, obsessive compulsive dis-
orders, eating disorders, post-traumatic 
stress disorders and substance abuse. In this 
context, quetiapine is one of the atypical 
neuroleptics that is most frequently pre-
scribed for off-label use, particularly at low 
dosages (1–6). This is especially relevant in 
the elderly, since the risk of receiving inap-
propriate medication is higher in this group 
in view of their numerous co-morbidities 
and the associated polypharmacy. Such cases 
have been observed particularly in elderly 
residents in retirement homes (2–3, 5, 7–11). 
Quetiapine is not without side effects, and 
its use in the elderly, even at low doses, is 
associated with numerous serious adverse 
reactions, including hip fractures, orthostatic 
hypotension or bouts of pneumonia (2–3, 5–
8, 12). The risk of drug interactions is also in-
creased due to the polypharmacy that is fre-
quently associated with these patients (7, 11, 
13). Various studies have shown a 1–2 % in-
crease in the mortality rate in elderly demen-
tia patients treated with neuroleptics, even 
at low dosages, which prompted the US 
Food and Drug Administration (FDA) to issue 
a warning as early as 2005 (2–5, 7–8). More-
over, hardly any evidence confirming effi-
cacy is available for the various off-label in-
dications of quetiapine. For example, various 
studies have shown not only that quetiapine 
is no better than placebo – from either the 
statistical or clinical standpoint – in treating 
agitation or psychoses in elderly dementia 
sufferers (15–20), but also that the long-term 
use of quetiapine is associated with signifi-
cant cognitive and functional deficits in el-
derly dementia patients compared to groups 
of comparable individuals that were not 
treated with quetiapine (15–17). 
The problem of the too frequent prescribing 
of quetiapine and its off-label use is not only 
discussed extensively at international level, 
but is also important at the local level: Spe-
cifically, a report produced in 2011 on the 
state of health of elderly residents in retire-
ment homes in Ticino showed that neurolep-
tics are prescribed much more frequently, on 
average, in Ticino than in Switzerland as a 
whole (14). The widespread off-label use of 
this drug in our canton has also been con-
firmed for hospitals: A project undertaken in 
2016 at the larger hospitals in the Cantonal 
Hospital Network (Ente Ospedaliero Canton-
ale, EOC) revealed that 54.6 % of the inves-
tigated prescriptions for quetiapine were for 
non-officially authorised indications. 
Objective 
The aim of this project was to ascertain the 
situation regarding the use of quetiapine in 
retirement homes in Ticino by analysing data 
on the consumption and, in particular, on 
the indications and the prescribers. 
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Method 
The collected and fully anonymised data 
were provided by the pharmacies in 15 re-
tirement homes in Ticino. The following was 
recorded: treatments with quetiapine in re-
lation to the overall number of retirement 
home residents, the prescribed dosage and 
posology (baseline and/or as-needed), the 
indication, the prescriber and demographic 
data. 
The study covered the period from Septem-
ber to November 2016 and included all resi-
dents in the retirement homes who received 
a baseline and/or as-needed treatment with 
quetiapine on the key date of the data sur-
vey. The statistical analysis of the frequency 
of off-label treatments with quetiapine ac-
cording to prescriber (general practitioner or 
specialist) was carried out with a 2x2 contin-
gency table with calculation of the odds ra-
tio, a confidence interval of 95 % and deter-
mination of the p value by Fisher's exact test. 
Results 
The data from 1,173 retirement home resi-
dents were analysed. 379 (32.3 %) of these 
patients were treated with quetiapine, and 
there were a total of 476 prescriptions (base-
line and/or as-needed). 73.4 % (n=278) of 
the patients treated with quetiapine were 
women, and the average age was 85.8 years. 
58.8 % (n=223) of the retirement home resi-
dents received quetiapine as baseline treat-
ment, 15.6 % (n=59) on an as-needed basis 
only and 25.6 % (n=97) both as baseline and 
as-needed medication. 
In the majority of the prescriptions (87.8 %, 
n=418), the dosage of quetiapine was less 
than 100 mg/day; the most commonly pre-
scribed dosages were less than 25 mg/day 
(53.6 %, n=255). Dosages of over 200 
mg/day, as recommended for the indications 
officially recognised by Swissmedic, ac-
counted for 4.4 % (n=21) of the prescrip-
tions (see figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Prescribed daily dose for quetiapine (Ntot=476), as-needed and baseline 
 
 
As far as the indications are concerned, quet-
iapine was prescribed for officially author-
ised indications (on-label) in 4.8 % (n=23) of 
cases, whereas an off-label indication was in-
volved in 94.3 % (n=449) of cases, particu-
larly for the treatment of agitation (31.3 %, 
n=149), dementia (30.3 %, n=144), anxiety 
states (15.3 %, n=73), depression (12 %, 
n=57), insomnia (6.7 %, n=32) and episodes 
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of delirium (4 %, n=19). Smaller percentages 
resulted for other indications, including sub-
stance abuse, post-traumatic stress disorders 
or obsessive compulsive disorders (see figure 
2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Indications for quetiapine (Ntot=476) 
As far as the prescribers are concerned, quet-
iapine was prescribed by general practition-
ers (family doctors or physicians working for 
the retirement homes) in 75 % (n=295) of 
cases, and by specialists (in geriatrics or psy-
chiatry) in 13.2 % (n=52) of cases. In 11.7 % 
(n=46) of cases, the prescribers could not be 
determined because the corresponding in-
formation was missing, or because the drug 
had been prescribed during a previous hos-
pital stay (see figure 3). A statistically signif-
icant link emerged between off-label pre-
scribing of quetiapine and prescribing by 
general practitioners (OR 3.01; 95 % CI, 
1.09–8.31; p=0.039). 
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Figure 3: Prescriber of quetiapine (Ntot=476) 
 
Conclusion 
The results confirm that quetiapine is widely 
used in retirement homes in Ticino: A third 
of the residents are treated with this medi-
cine. Quetiapine was administered mainly at 
low dosages for an off-label indication, par-
ticularly for the treatment of agitation and 
dementia. 
A statistically significant link also emerged 
between the off-label prescribing of queti-
apine and the prescribing by general practi-
tioners compared to specialists. 
Efforts to raise awareness among general 
practitioners about the off-label use of quet-
iapine and, possibly, the increased involve-
ment of specialists in the prescribing of 
drugs in retirement homes may help reduce 
the frequency of prescription of this drug in 
inappropriate cases, and thereby improve 
the care of the elderly. 
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Regulatory 
The Guidelines for Quality Assurance in 
Transfusion Practice – An introduction 
with examples 
Introduction 
Quality assurance in the context of blood 
transfusions is crucial to providing patients 
with the best possible treatment, avoiding 
transfusion errors and preventing harm to pa-
tients. Hence the formation in 2015 of the 
Swiss "Quality Assurance in the Use of Blood 
Products" working group. The group first 
published the "Guidelines for Quality Assur-
ance in Transfusion Practice" in June 2017. 
Composition of the working group 
The working group comprises representatives 
from among the Cantonal Medical Officers, 
Cantonal Pharmacists, Haemovigilance Offic-
ers and Swissmedic experts. The final guide-
lines have been approved by all the bodies re-
sponsible for oversight of transfusion activi-
ties: the Association of Cantonal Medical Of-
ficers, Association of Cantonal Pharmacists, 
Swissmedic and the Swiss Transfusion Medi-
cine Association (STMA). 
Binding nature of the guidelines 
The guidelines take account of the status of 
the legislation and knowledge at the time of 
publication and are designed to help the 
transfusion institutions (users) set up or check 
the legally stipulated QA system. The users 
may implement procedures that deviate from 
these recommendations if, on the basis of the 
latest scientific findings, it can reliably be as-
sumed that the desired quality and safety 
goals in these guidelines are achieved to the 
equivalent extent or better. 
Classification and definition 
Article 39, paragraph 4 of the Swiss Therapeu-
tic Products Ordinance (TPO) requires users to 
observe the following: 
“Institutions that use labile blood products 
shall establish a quality assurance system for 
the use of labile blood products according to 
the current state of medical science and tech-
nology. They shall designate an individual 
who is responsible for fulfilling the reporting 
obligations.” 
These guidelines specify the minimum re-
quirements for this quality assurance in trans-
fusion practice in the form of a list of criteria. 
They also specify further requirements and 
recommendations. The following deserve 
particular mention: Transfusion medicine la-
boratory tests on patient samples, recommen-
dations of the STMA and the Blood Transfu-
sion Service of the Swiss Red Cross for profes-
sionals, laboratories and medical institutions 
on immunohaematology and molecular in-
vestigations on patients' blood samples. 
These recommendations and the guidelines 
largely complement each other and cover all 
the processes in the transfusion chain from 
the standpoint of the user. 
Haemovigilance data 
In addition to international data and guide-
lines, the key themes and content of the Swiss 
guidelines are based on Swiss haemovigilance 
data – specifically reports from hospitals con-
cerning not just transfusion reactions, but 
also reports of transfusion errors and "near 
misses". Near misses are errors or deviations 
from standard operating procedures or direc-
tives that are discovered before initiating a 
transfusion and that could have resulted in a 
transfusion error or a transfusion reaction in 
the recipient if the error/deviation had not 
been detected and corrected. 
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Figure 1: Near miss reports in Switzerland 2008–2017 
 
Figure 1 shows the near misses reported since 
2008: 
Around 15% of the cases involve a grade 3 
near miss, i.e. they are potentially life-threat-
ening (in absolute figures: 2015: 147; 2016: 
150; 2017: 272). 
Most of the grade 3 near misses involve 
"Wrong Blood in Tube" (WBIT) cases, which 
means that mix-ups occurred in respect of pa-
tients or samples taken before transfusion (1). 
These mix-ups can lead to ABO-incompatible 
transfusion errors if the error is not discov-
ered before the transfusion. 
Due to under-reporting, it can therefore be 
assumed that several hundred such mix-ups 
occur in Switzerland each year and threaten 
the lives of patients. Quality assurance 
measures are therefore essential. 
Example 1: Duplicate blood group (BG) 
determinations 
ABO-incompatible transfusion errors are life-
threatening, even though the earlier mortal-
ity rate of approx. 10% probably no longer 
applies thanks to better monitoring (2). The 
present rate cannot be determined precisely 
since such incidents are so rare. One of the 
most important measures for avoiding trans-
fusion errors in Switzerland is duplicate blood 
group determination. This severely limits the 
greatest risk, namely the mix-up of samples or 
patients during sampling. In Switzerland – in 
contrast to Germany, for example – the BG 
check is only rarely performed at the patient's 
bedside (bedside test). 
Quote from the guidelines: 
"At least two blood group determinations are needed 
for each transfusion of labile blood products in order to 
detect any mix-ups. If the blood group is not yet known, 
one complete blood group determination should al-
ways be carried out on two independently taken blood 
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samples with separate patient identification for each 
sample. 
The QA system stipulates which external documents are 
accepted as BG determinations (e.g. BG cards) and 
which are not…." 
Example 2: Checks when hanging up the 
transfusion 
The above-mentioned WBIT errors are the 
most commonly reported grade 3 near misses. 
However, there is another important cause of 
transfusion errors that are actually observed 
in practice: According to the Swiss haemovig-
ilance data, more than half of ABO transfu-
sion errors (ABO incompatible or compatible 
only by chance) result from incorrect patient 
identification just before initiation of the 
transfusion (1). 
Quote from the guidelines: 
"The checks before the administration of the transfu-
sion should be carried out by two registered nurses (vo-
cational college/university of applied sciences) who 
have been trained for and are authorised to perform 
this task, one of whom may still be in training. Both in-
dividuals should check independently of each other; a 
registered nurse (vocational college/university of ap-
plied sciences) executes the transfusion [….] 
The patient's identity and blood group (on the bag and 
on the documentation) are checked at the patient's 
bedside and immediately before the transfusion, usually 
by two people: 
 Identify the patient by asking him/her to state 
his/her name (if possible). 
 Check the blood group compatibility between the 
product and patient. 
 Check the conformity of the patient's details (first 
name, surname, full date of birth) with the current 
blood group card or laboratory report, the blood 
bag sticker and the details on the blood product. 
 Check the validity of the pre-transfusion tests. 
An electronic patient identification system can replace 
one of the two checkers as an independent check prior 
to administration at the patient's bedside. In addition 
to the electronic check, the registered nurse (vocational 
college/university of applied sciences) must also ask the 
patient to state his/her name." 
Link to the guidelines 
The guidelines are also available on the web-
sites of the following bodies that are respon-
sible for monitoring transfusion activities: 
 Association of Cantonal Pharmacists 
 Association of Cantonal Medical Officers in 
Switzerland 
 Swissmedic 
 Swiss Transfusion Medicine Association 
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Periodic Safety Update Reports (PSUR) – 
Important mainstay of drug safety 
For many years, the market surveillance of an 
authorised medicinal product has included 
the need for the marketing authorisation 
holder to submit a PSUR to Swissmedic at reg-
ular intervals as a condition of the authorisa-
tion. While this applies to both human and 
veterinary medicinal products, the present ar-
ticle deals only with human medicines. 
The submission procedure at Swissmedic has 
changed over time. In previous years, PSUR 
used to be submitted twice a year, starting 
from the day of authorisation in Switzerland, 
and each report covered a period of six 
months. Swissmedic subsequently switched to 
the annual submission of two six-monthly 
PSUR. PSUR usually have to be submitted for 
a period of five years. In the event of a rele-
vant indication extension, e.g. from use in 
adults to use in children as well, the obliga-
tion to submit PSUR was extended for a fur-
ther five years from the date of the official 
decision approving the indication extension. 
Swissmedic also has the option of extending 
the obligation to submit PSUR in connection 
with a review procedure or signal investiga-
tion, or to reset the obligation when it has al-
ready expired. 
The structure of a PSUR is determined by the 
International Conference on Harmonisation 
(ICH). For details refer to ICH E2C(R2) dated 17 
December 2012. Aspects that are directly or 
indirectly associated with drug safety include 
completed clinical trials, long-term follow-up, 
new safety data related to combination ther-
apies and signals. 
For signals, the author of the PSUR is required 
to state, clearly and comprehensively, the rea-
sons for or against a causal relationship with 
the product and to arrive at an evaluation of 
one of the following three options: 
 The signal is refuted since the available 
evidence argues against a causal relation-
ship. 
 The signal is declared to be an identified 
risk since the evidence is sufficient to indi-
cate an association with the product. 
 The signal is declared to be a potential risk. 
There are reasons for suspecting a relation-
ship, but this cannot yet be con-
firmed/proved. 
One important mandatory aspect of a PSUR is 
“Actions Taken in the Reporting Interval for 
Safety Reasons”. The actions that were taken 
during the reporting interval for safety rea-
sons and that need to be included in the re-
port relate to the MAH (Marketing Authori-
sation Holder), the sponsor of a clinical trial, 
Data Monitoring Committees, ethics commit-
tees and, of course, regulatory authorities. 
The actions cover both regular market use 
and new therapeutic areas (investigational 
use). 
In the section “Level of Detail Within PBRER”, 
the ICH Guideline gives the author a certain 
amount of leeway regarding the scope and 
depth of the presentation. It is clear that no 
single benchmark can be set for the numerous 
products subject to the PSUR obligation. On 
the other hand, the responsibility for cor-
rectly interpreting this leeway therefore rests 
with the author. It is not just the description 
that is needed but, above all, the medical 
evaluation – and here it is important to avoid 
focusing solely on one’s own product. 
The author should also take a conscientious 
look at similar preparations, other therapeu-
tic options, new findings in diagnosis or treat-
ment, and the options for prevention, in each 
case taking into account the risk, impact on 
the patient, options for the physician and the 
life cycle of the product.  
It is also desirable to think about the target 
readership, i.e. the authority's individuals 
who process the PSUR. Clearly presented text 
and tables and the use of helpful illustrations 
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can assist the Clinical Reviewer, but possibly 
also the MAH itself. At the very least, it leaves 
a good impression if a PSUR for a "difficult" 
product is well presented. 
During the ICH Assembly in Kobe/Japan from 
1-7 June 2018, the E19 EWG on Optimization 
of Safety Data Collection met, in addition to 
other working groups. The meeting aimed to 
separate the " wheat from the chaff" in con-
nection with data collection, i.e. to record 
only the relevant safety data while preserving 
the risk-based approach. 
 
Development of PSUR completions from 2012 to June 2018 
 
 
Thanks to the extended IT support and inter-
nal improvements at Swissmedic, the pro-
cessing time has shortened appreciably in re-
cent years, and is currently six weeks on aver-
age (42 calendar days). 
For some years now, PSUR submissions to 
Swissmedic have been accompanied by a new 
version of a Risk Management Plan (RMP), 
known as an RMP Update. The simultaneous 
submission not only simplifies matters for the 
processing specialist, but also enhances the 
efficiency of the assessment and thus, ulti-
mately, improves drug safety. 
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Overview of PSUR completions including RMP Updates in recent years 
 
 
 
In a new RMP Update, the author not only 
reviews the changes compared to the previ-
ous version and their implications for the 
safety profile, but also checks whether 
changes need to be made to the RMP Sum-
mary, which the authorisation holder makes 
available to Swissmedic for publication on 
the Agency’s website. 
A key component of an RMP is the Summary 
of Safety Concerns. This is where the im-
portant identified risks, important potential 
risks and missing information are presented 
in a table together with a summary descrip-
tion. This section is linked to the PSUR in that 
all points in the Safety Concerns must be re-
addressed and reassessed in every PSUR. As a 
result, no risk can be "hidden" in what is of-
ten a very voluminous PSUR. 
Companies are required to submit relevant 
RMP Updates only. In this context, it is help-
ful to include a specific reference to this ei-
ther in the mandatory Swissmedic PSUR form 
or in the cover letter. 
What is the aim of PSUR submissions? 
What are the implications for drug safety? 
 While preparing the PSUR, the MAH dis-
covers that the product information in 
Switzerland needs to be modified in re-
spect of a particular adverse reaction. 
 While evaluating the PSUR, Swissmedic 
discovers that immediate action needs to 
be taken in respect of an adverse reac-
tion, or that certain points must be clari-
fied in the next PSUR, e.g. through addi-
tional evaluations, more detailed descrip-
tion (including graphs) and an in-depth 
evaluation by the company. 
 While comparing the Safety Concerns of 
the RMP and PSUR, Swissmedic discovers 
that the risk minimisation measures de-
scribed by the company in the RMP do not 
lead to the desired objective. 
 The effectiveness of a product under mar-
ket conditions produces results that differ 
from those from the clinical trials that led 
to the authorisation. 
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 For Orphan Drugs the data pool is very 
limited due to the rarity of the disease 
and starts to grow only after market 
launch. The growing experience is re-
flected in the PSUR. 
For various reasons it is not appropriate to 
publish statistics on the countable results or 
results that are visible to third parties (out-
come of drug safety). These reasons include 
overlaps in content with authorisation pro-
cesses or the poorly quantifiable effect of 
publication of a Direct Healthcare Profes-
sional Communication (DHPC). 
The new Therapeutic Products Act, TPA 2, 
will shorten the mandatory period for sub-
mitting PSUR in Switzerland from the stand-
ard five years to four years. Swissmedic be-
lieves that this decision will not adversely af-
fect drug safety. 
One reason is the more comprehensive and 
improved pharmacovigilance as a result of: 
 increased reporting frequencies in recent 
years, 
 reports of adverse reactions by patients as 
well, 
 the reporting of signals by authorisation 
holders, which is independent of the 
PSUR obligation, 
 intensive international collaboration. 
Conclusion: PSUR remain an intellectual and 
ethical challenge, both for those who pro-
duce them and those who evaluate them. 
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Statistical Review 2017 
Vigilance of human medicines 
Within the framework of the pharmacovigi-
lance network, the direct reports from profes-
sionals and patients on adverse drug reac-
tions are assessed in six regional pharma-
covigilance centres (RPVC) on behalf of Swiss-
medic and recorded in the national database. 
The professionals who submit the reports re-
ceive appropriate feedback. Reports on ad-
verse reactions from within Switzerland are 
also sent to Swissmedic by the pharmaceutical 
companies. 
Activities 
• In the year under review, Swissmedic re-
ceived 9,637 initial reports of suspected ad-
verse drug reactions (ADR) associated with 
medicinal products, evaluated them and 
recorded them in the national VigiFlow da-
tabase. The regional pharmacovigilance 
centres (RPVC) sent 2,574 reports, the phar-
maceutical industry 7,063. In addition, 
4,207 follow-up reports were processed 
and evaluated. 
• The proportion of reports from the phar-
maceutical industry that were submitted 
electronically increased to nearly 100 %. 
90 % of these reports reached Swissmedic 
via the Pharmacovigilance Gateway (25 
firms), the remainder via the online report-
ing portal ElViS (electronic vigilance sys-
tem). 
• The preparations for the introduction of a 
new, modern pharmacovigilance database 
in 2018, which took place in parallel to day-
to-day business, represented a particular 
challenge and dominated the working day 
in the year under review. 
Figure 1: Adverse drug reactions, human 
medicinal products: Number of initial reports 
from 
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Vaccinovigilance 
Summary of adverse events following 
immunization reported in Switzerland 
During 2017, Swissmedic received 232 case re-
ports of suspected adverse events following 
immunization (AEFI) from Switzerland. This is 
a higher level than the number of cases sub-
mitted during 2016 (209 reports) but lower as 
compared to 2015 (278 reports). However, 
during 2015, 80 of 278 reports had been ret-
rospectively submitted cases occurring in pre-
vious years. Since no retrospective reporting 
occurred during 2017, all 232 case reports 
contain recently occurring AEFI. Notably, 
there are no precise data available regarding 
the total number of vaccines/doses adminis-
tered during 2017 and therefore a straight-
forward conclusion regarding AEFI reporting 
 
rates cannot be drawn. As previously, Swiss-
medic is encouraging spontaneous reporting 
of AEFI with high quality, which enables early 
detection of new safety signals. Since 2010, 
important safety topics concerning vaccines – 
including potential risks – are being discussed 
and evaluated by experts of the Swissmedic 
Human Medicines Expert Committee (HMEC). 
An increased AEFI reporting rate followed by 
a scientific evaluation of relevant cases can 
lead to new risk minimisation measures in or-
der to ensure vaccine safety, if necessary. 
Complete report: 
Vaccinovigilance – Adverse events following 
immunization – annual report 2017 
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Information on the Swissmedic website1 
Healthcare Professional Communication 
22.09.2018 
DHPC – Litak® 10 (Cladribin)  
Risiko einer progressiven multifokalen Leukenze-
phalopathie (PML) 
 
19.09.2018 
DHPC – Spinraza® (Nusinersen)  
Berichte über das Auftreten eines kommunizie-
renden Hydrozephalus, der nicht mit einer Me-
ningitis oder Blutung in Verbindung steht 
 
07.09.2018 
DHPC – Remodulin (Treprostinil) Infusionslösung  
Anpassung der Arzneimittelinformation 
 
06.09.2018 
HPC – Condrosulf® (Chondroitinsulfat), Struc-
tum® (Chondroitinsulfat)  
Abschluss der Überprüfung Chondroitinsulfat-
haltiger Arzneimittel – Anpassung der Indikation 
 
24.08.2018 
DHPC – Esmya® (Ulipristalacetat)  
Indikationseinschränkung, neue Kontraindikation 
und Notwendigkeit zur Durchführung von Leber-
funktionstests bei der Anwendung von Uliprista-
lacetat, Esmya® 5 mg Tabletten 
 
22.08.2018 
DHPC – Thiopental Inresa  
As a precautionary measure, the use of Thiopen-
tal Inresa should be strictly indicated until further 
notice 
 
14.08.2018 
DHPC – ZINBRYTA® (Daclizumab beta)  
Berichte über immunvermittelte Enzephalitis, ein-
schliesslich Anti-NMDA-rezeptorvermittelte Enze-
phalitis, mehrere Monate nach Absetzen 
 
08.08.2018 
DHPC – Cinryze® 500 IU, Pulver und Lösungsmit-
tel  
Shire Switzerland GmbH informiert über die ein-
geschränkte Verfügbarkeit  
13.06.2018 
DHPC – Perenterol 250 (Saccharomyces boulardii) 
Kapseln und Beutel  
Neue Kontraindikation von Saccharomyces bou-
lardii bei schwerkranken Patienten 
 
13.06.2018 
DHPC – XGEVA (Denosumab)  
Risiko multipler vertebraler Frakturen (MVF) im 
Zusammenhang mit Knochenmineralverlust nach 
Absetzen / Risiko für neue primäre maligne Er-
krankungen (NPM) 
 
08.06.2018 
DHPC - Tivicay® (Dolutegravir) /Triumeq® (Dolut-
egravir/Abacavir/Lamivudin)  
Dolutegravir: Neuralrohrdefekte (Neural Tube 
Defect, NTD) bei Neugeborenen von Frauen, die 
zur Zeit der Konzeption im Rahmen der Tse-
pamo-Studie mit Dolutegravir behandelt wurden 
 
 
 
Announcements 
05.11.2018 
Valsartan: Proprietary medicines on the Swiss mar-
ket containing sartans are safe in respect of NDMA  
Analytical results to date for the proprietary me-
dicinal products containing the active substances 
valsartan, losartan, olmesartan, candesartan and 
irbesartan 
 
05.11.2018 
Analytical results for NDMA tested medicinal 
products with sartans  
Analytical results in respect of NDMA for the pro-
prietary medicinal products containing the active 
substances valsartan, losartan, olmesartan, can-
desartan and irbesartan. 
1 Most of the links are available in German/French only 
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05.11.2018 
Aktueller Stand bei Zulassungen von homöopathi-
schen und anthroposophischen Arzneimitteln 
ohne Indikation  
 
02.11.2018 
Federal Council approves Swissmedic's strategic 
goals for 2019–22  
Swissmedic guarantees efficient, independent 
therapeutic products oversight. 
 
01.11.2018 
New application forms for operating licences 
available  
 
01.11.2018 
Update of eCTD and eDok specification docu-
ments  
Documents are valid with immediate effect. 
 
23.10.2018 
Operation "PANGEA XI": Switzerland participates 
in international week of action against illegal 
trading in medicines  
Successful operation against illegal online sales 
 
01.10.2018 
Valsartan: Extended investigations – products on 
Swiss market tested to date give no cause for con-
cern  
Like the previously analysed products with valsar-
tan, products with losartan, olmesartan and can-
desartan that have been investigated do not con-
tain elevated NDMA levels. 
 
30.09.2018 
Procedure for submitting applications according 
to HMV4 before 1 January 2019  
As of 1 December 2018 Swissmedic will accept sub-
missions with the documents updated according 
to HMV4. 
 
30.09.2018 
Updating of various specification documents con-
nected with HMV4  
Various eDok and eCTD specification documents 
are being updated 
 
30.09.2018 
Revision of the Therapeutic Products Act (TPA): 
Publication of the specification documents and 
forms for authorisation applications  
Owing to the revision of the TPA and the corre-
sponding implementing ordinances (Therapeutic 
Products Ordinance Package IV), Swissmedic has 
adapted the specification documents and forms 
for authorisation applications. 
 
25.09.2018 
New process GMP/GDP-certificates  
As of 1 January 2019 GMP/GDP certificates to be 
ordered exclusively via eGov GMP-GDP service 
 
21.09.2018 
Therapeutic Products Ordinance Package IV: Pub-
lication of the ordinances  
The Federal Council has approved Therapeutic 
Products Ordinance Package IV. Swissmedic and 
the FOPH publish the revised documents 
 
18.09.2018 
Publikumswerbung für zugelassene Komplemen-
tärarzneimittel ohne Indikation  
Regulierende Massnahmen von Swissmedic 
 
14.09.2018 
New application forms for operating licences 
available from November 2018 
 
14.09.2018 
Swissmedic agrees closer collaboration in thera-
peutic products field with Dutch partner authority  
Swissmedic intends to intensify collaboration with 
its partner authority in the Netherlands 
 
13.09.2018 
Adverse events following immunization – annual 
Vaccinovigilance report  
Summary of adverse events following immuniza-
tion reported in Switzerland during 2017 
 
07.09.2018 
F&A Umteilung Abgabekategorien  
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06.09.2018 
Swiss eCTD: Updating of Module 1 as of January 
2019  
Changes to the specifications (folder structure) in 
Module 1 of the Swiss eCTD module due to the re-
vision of the Therapeutic Products Ordinances 
 
01.09.2018 
Amendments to the “MB Swissmedic eGov Portal 
– Standard Functions” information sheets  
OS000_00_001d_MB / OS000_00_002dMB 
 
31.08.2018 
Swissmedic eGovernment services: New customer 
portal  
System enhancements and new eGov service as of 
September 2018 
 
27.08.2018 
Abteilung Betäubungsmittel Info & News 2018  
Swissmedic Veranstaltung 
 
24.08.2018 
Medicinal products containing valsartan: First an-
alytical results  
Preparations with valsartan that are currently 
available on the market satisfy the requirements 
 
17.08.2018 
Investigation of Valsartan medicinal products for 
evidence of active substance contamination – an 
update  
Additional recall of batches in Europe – no prod-
ucts in Switzerland affected to date 
 
15.08.2018 
Revision des Heilmittelgesetzes (HMG)  
Informationsveranstaltung 2018 
 
09.08.2018 
Spontanmeldungen aus der Schweiz zu hormona-
len Kontrazeptiva und venösen Thromboembolien 
aktualisierte Zahlen mit Stand 30.06.2018 
 
07.08.2018 
Individual distinguishing features and safety pre-
cautions on the packaging of medicinal products  
two-dimensional barcodes (data matrix) 
 
03.08.2018 
(BIA-ALCL) Anaplastic large cell lymphomas in con-
nection with breast implants – updated infor-
mation  
Affected products: Breast implants, all types, 
makes and models of all manufacturers 
 
03.08.2018 
Safety notice: Recall of three varieties of latex-free 
condoms – Durex Natural Feeling (pack of 10 con-
doms), Durex Love Collection (pack of 31 con-
doms) and Durex Natural Feeling Easy Glide (pack 
of 12 condoms) – produced by Reckitt Benckiser 
Healthcare (UK) Limited 
 
18.07.2018 
Adaptation of the Guidance document «Time lim-
its for authorisation applications» to be submitted 
immediately  
ZL000_00_006e_WL 
 
12.07.2018 
List of authorised products containing valsartan as 
active substance  
List of preparations and batches affected by the 
batch recall 
 
10.07.2018 
Änderungen der Liste der dokumentierten traditi-
onellen asiatischen Stoffe  
Liste TAS gemäss Anhang 6 Art. 29 Abs.1 (KPAV; 
SR 812.212.24) und des Vorworts zur Liste TAS 
 
10.07.2018 
Changes to the Guidance document on time limits 
for authorisation applications  
The changes to the Guidance document take im-
mediate effect. 
 
06.07.2018 
Impurities in valsartan products: risks currently be-
ing investigated  
Certain preparations containing the active sub-
stance valsartan produced by a Chinese manufac-
turer are in some cases being recalled in Europe 
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04.07.2018 
ICH Assembly in Kobe, Japan, 2 to 7 June 2018  
ICH continues membership expansion, and ad-
vances harmonisation work in electronic standards 
and pharmaceutical quality 
 
01.07.2018 
Nachtrag 9.5 der Europäischen Pharmakopöe in 
Kraft  
Der Institutsrat hat den Nachtrag 9.5 der Europäi-
schen Pharmakopöe auf den 1. Juli 2018 in Kraft 
gesetzt. 
 
29.06.2018 
Warning regarding eye contact with the veteri-
nary medicinal product Osurnia® ad us.vet.  
In both humans and dogs, the ear gel for dogs 
coming into contact with eyes can result in eye ir-
ritation, redness of the eye and in very rare cases 
corneal ulcers 
 
18.06.2018 
HIV self-test kits now also available in Switzerland  
Media release 
 
04.06.2018 
Swissmedic Annual Report 2017: achieving success 
through collaboration  
“The Agency fulfils its mandate reliably and pro-
fessionally”  
 
 
 
The complete list is available at the following 
web address www.swissmedic.ch/updates-en 
